| (USD) | Dec 2023 | Q/Q |
|---|---|---|
| Revenue | 0 | - |
| Operating Income | -33.2MM | -2% |
| Operating Expenses | 33.2MM | -2% |
| Net Income | -30.9MM | -2% |
| R&D | 26.8MM | -1% |
| G&A | 6.5MM | -6% |
| Amortization | 317K | +6% |
Short Volume Ratio = Short Volume / All Volume. Source of Short Volume data comes from
FinraMoving Average Convergence/Divergence oscillator (MACD) is one of the simplest and most effective momentum indicators available.
Relative Strength Index (RSI) is a momentum oscillator that measures the speed and change of price movements. RSI oscillates between zero and 100. According to Wilder, RSI is considered overbought when above 70 and oversold when below 30.
- Confirmed objective response rate (ORR) of 15.6% in all patients regardless of PD-L1 or HPV status - Confirmed ORR of 17.4% in subset of patients with PD-L1+ disease - Confirmed ORR of 22.2% in subset of patients with HPV+ disease - Median duration of treatment in responders was 19.6 months at the time of data cutoff SOUTH SAN FRANCISCO, Calif., April 09, 2024 (GLOBE NEWSWIRE) -- RAPT Therapeutics, Inc. (Nasdaq: RAPT), a clinical-stage, immunology-based therapeutics company focused on discover
It is not a bad idea to hunt for biotech stocks to sell. Such stocks have earned a bad reputation among investors, and for good reason. Most biotech companies fail, as their success often hinges on receiving regulatory approval for their products. It is an extremely high-risk sector to invest in. For every promising biotech company that successfully navigates clinical trials and generates multibagger returns, there are 99 others that either fail outright or struggle to deliver any gains at all.
TimesSquare Capital Management, an equity investment management company, released its “U.S. Small Cap Growth Strategy” fourth-quarter investor letter. A copy of the same can be downloaded here. In the quarter the fund returned 9.15% (net), compared to a 12.75% return for the Russell 2000 Growth Index. For the year, the fund returned 15.96% (net) compared to […]
RAPT Therapeutics (RAPT) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.
Company maintains solid cash position of $158.9 millionSOUTH SAN FRANCISCO, Calif., March 07, 2024 (GLOBE NEWSWIRE) -- RAPT Therapeutics, Inc. (Nasdaq: RAPT), a clinical-stage, immunology-based therapeutics company focused on discovering, developing and commercializing oral small molecule therapies for patients with significant unmet needs in inflammatory diseases and oncology, today reported financial results for the fourth quarter and year ended December 31, 2023. “We are working diligently to
Includes late-breaking poster presentation to highlight phase 2 clinical data for tivumecirnon in head and neck cancerSOUTH SAN FRANCISCO, Calif., March 05, 2024 (GLOBE NEWSWIRE) -- RAPT Therapeutics, Inc. (Nasdaq: RAPT), a clinical-stage, immunology-based therapeutics company focused on discovering, developing and commercializing oral small molecule therapies for patients with significant unmet needs in inflammatory diseases and oncology, today announced the acceptance of three late-breaking ab
The recent price decline of 73% in RAPT Therapeutics, Inc.'s ( NASDAQ:RAPT ) stock may have disappointed insiders who...
Biotech stock Rapt plummeted to a record low Tuesday after the Food and Drug Administration put two of its clinical studies on hold.
RAPT Therapeutics said the Food and Drug Administration has placed a hold on two trials of the drug zelnecirnon after a patient taking it suffered liver failure. Shares of RAPT were down 63% to $9.49 on Tuesday. The halt has been placed on a Phase 2b trial of zelnecirnon in atopic dermatitis and a Phase 2a trial in asthma, the company said.
Rapt Therapeutics said on Tuesday the U.S. FDA had placed on hold two mid-stage trials of the company's drug to treat eczema and asthma, after liver failure was observed in one of the patients. The company said it had enrolled 350 patients across the two mid-stage trials and a previous early-stage study of the drug, zelnecirnon, but no evidence of liver toxicity was observed with any other patient. Following the hold, Rapt will halt dosing of existing patients and stop enrollment of new partic...